Background
Methods
Patients
Study Design
Assessments and Analyses
Results
Patients
Characteristic | Everolimus 5 mg/day (n = 12) | Everolimus 10 mg/day (n = 12) |
---|---|---|
Median (range) age, y | 55 (27-75) | 56 (32-75) |
Sex, n (%) | ||
Male | 5 (41.7) | 4 (33.3) |
Female | 7 (58.3) | 8 (66.7) |
WHO performance status, n (%) | ||
0 | 3 (25.0) | 1 (8.3) |
1 | 9 (75.0) | 9 (75.0) |
2 | 0 | 2 (16.7) |
Prior antineoplastic therapy, n (%) | ||
Surgery | 11 (91.7) | 10 (83.3) |
Radiotherapy | 3 (25.0) | 3 (25.0) |
Chemotherapy | 10 (83.3) | 10 (83.3) |
Targeted therapy | 5 (41.7) | 5 (41.7) |
Immunotherapy | 3 (25.0) | 2 (16.7) |
Hormonal therapy | 2 (16.7) | 0 |
Everolimus 5 mg/day (n = 12) | Everolimus 10 mg/day (n = 12) | |
---|---|---|
Ongoing, n (%) | 2 (16.7) | 1 (8.3) |
Discontinued, n (%) | 10 (83.3) | 11 (91.7) |
Patient withdrew consent | 1 (8.3) | 2 (16.7) |
Death | 0 | 2 (16.7) |
Disease progression | 9 (75.0) | 7 (58.3) |
Treatment Exposure
Pharmacokinetics
Parametera | Everolimus 5 mg/day (n = 12) | Everolimus 10 mg/day (n = 12) |
---|---|---|
AUC0-τ, h•ng/mL | 316.1 (34.8) | 588.6 (41.4) |
CL/F, L/h | 15.8 (34.8) | 16.99 (41.4) |
Cmax, ng/mL | 28.8 (31.3) | 53.8 (56.2) |
Tmax, h (range) | 2.96 (1.00-4.00) | 2.0 (0.92-6.00) |
Cmin, ng/mL | 8.3 (46.8) | 14.5 (47.9) |
Safety
Everolimus 5 mg/day (n = 12) | Everolimus 10 mg/day (n = 12) | |||||
---|---|---|---|---|---|---|
Adverse event, n (%) | All grades | Grade 3 | Grade 4 | All grades | Grade 3 | Grade 4 |
Total
|
12 (100)
|
3 (25.0)
|
0
|
12 (100)
|
3 (25.0)
|
0
|
Hyperglycemia | 2 (16.7) | 0 | 0 | 5 (41.7) | 1 (8.3) | 0 |
Fatigue | 2 (16.7) | 0 | 0 | 4 (33.3) | 1 (8.3) | 0 |
Anemia | 1 (8.3) | 1 (8.3) | 0 | 3 (25.0) | 0 | 0 |
Blood alkaline phosphatase increased | 1 (8.3) | 0 | 0 | 3 (25.0) | 1 (8.3) | 0 |
Thrombocytopenia | 2 (16.7) | 1 (8.3) | 0 | 3 (25.0) | 0 | 0 |
Hypokalemia | 3 (25.0) | 1 (8.3) | 0 | 2 (16.7) | 0 | 0 |
Upper respiratory tract infection | 1 (8.3) | 1 (8.3) | 0 | 0 | 0 |